Vaccine Adverse Events
by Jill Follows, JD, RN T he goal of annual influenza vaccination is to prevent seasonal influenza that, according to the Centers for Disease Control and Prevention (CDC), "causes approximately 200,000 hospitalizations and 36,000 deaths in the United States each year" (CDC, 2011) . For many workers, the seasonal trivalent influenza vaccination is an innocuous routine health event. The vaccination is readily accessible and affordable at places such as the occupational health office, lo-cal pharmacy or clinic, and private providers' offices. Side effects from the vaccination, if any, are usually mild and short term, and the vaccination makes sense financially. Workers may not have sick day benefits and may be the sole or primary wage earners for their families. Some workers cannot afford to stay home with debilitating fever, arthralgia, and myalgia.
Businesses cannot afford the loss in worker productivity associated with a flu outbreak. The CDC estimated the annual business losses for direct cost of hospitalizations and outpatient care during the 2010-2011 influenza season to be approximately $10 billion (CDC, 2011) . Recognizing the problem, the federal government encourages businesses to be proactive by creating seasonal immunization clinics. The government also sponsors a website where employers can download a toolkit on how to fight the flu (CDC, 2011) .
The government's 2010 Vaccine Information Statement (VIS) both reveals reasons for promoting seasonal trivalent influenza vaccination and cautions that for several categories of individuals, vaccination is problematic. The government advises those individuals with severe allergy to eggs to forego the flu shot. In addition, those individuals who have had a previous severe reaction after receiving a dose of the influenza vaccine should consult their health care providers for guidance. The government also acknowledges the existence of an outlier group of individuals who develop severe adverse reactions to the influenza vaccination but who are not medically predictable. The size of the outlier group is unknown.
For more than 25 years, the U.S. Court of Federal Claims, the "Vaccine Court," in Washington, DC, has decided the disposition of claims from petitioners alleging a serious vaccine injury. Within the past 5 years, injury associated with seasonal trivalent influenza vaccine has increasingly become a significant source of vaccine injury claims in the Vaccine Court.
Federal government concern about adverse events caused by vaccination (not limited to the influenza vaccine) resulted in federal legislation. In 1986, the U.S. Congress passed the "Vaccine Act" (National Childhood Vaccine Injury Act, 1986) with the intent of (1) ensuring the continued supply of safe vaccines, (2) protecting vaccine manufacturers and health care providers from liability suits, and (3) compensating individuals with substantiated vac-Millions of adults are vaccinated annually against the seasonal influenza virus. An undetermined number of individuals will develop adverse events to the influenza vaccination. Those who suffer substantiated vaccine injuries, disabilities, and aggravated conditions may file a timely, no-fault and no-cost petition for financial compensation under the National Vaccine Act in the Vaccine Court. The elements of a successful vaccine injury claim are described in the context of a claim showing the seasonal influenza vaccination was the cause of Guillain-Barré syndrome.
PROFESSIONAL PRACTICE
PROFESSIONAL PRACTICE cine injuries. In the process of drafting this legislation, Congress addressed both the nature and the scope of the problem by stating that "while most of the nation's children enjoy great benefit from immunization programs, a small but significant number have been gravely injured-it is not always possible to predict who they will be or what reactions to the immunizations they will have" (Knudsen, 1999). As originally drafted, the Vaccine Act compensated children for adverse effects to vaccines. Subsequently, with the addition of the seasonal trivalent influenza vaccine to the Vaccine Injury Table in 2005 , and the increased number of adults receiving vaccinations, the proportion of adult to child court filings for vaccine injuries changed (U.S. Department of Health and Human Services, Health Resources and Services Administration, 2011a).
VAERS
The federal government created a national database, the Vaccine Adverse Event Reporting System (VAERS), to capture the reports of severe adverse events and allergic reactions to seasonal influenza as well as other vaccines. The statistical reliability of the VAERS database is continually challenged, primarily because adverse event reporting is voluntary and sporadic and derives from many sources, including clients' firstperson accounts. The recent Institute of Medicine (2011) report on adverse effects of vaccines also suggested the need for improved case reporting when a vaccine injury was filed in the VAERS database or reported in the health care literature.
VACCINE INJURY COMPENSATION PROGRAM
The Vaccine Act established a national no-fault compensation program, the Vaccine Injury Compensation Program (VICP), to review the claims of clients or petitioners who allege a vaccine adverse event. Petitioners file vaccine injury claims in the U.S. Court of Federal Claims in Washington, DC. The petition always identifies the Secretary of Health and Human Services as the respondent in the vaccine claim.
The VICP is funded by an excise tax placed on the sale of each vaccine. The resulting Vaccine Injury Compensation Trust Fund pays out monetary awards (i.e., legal compensation) to petitioners filing substantiated vaccine injury claims as well as fees to petitioners' expert witnesses and attorneys. The balance in the Fund, as of June 30, 2011, exceeded $3 billion (U.S. Department of Health and Human Services, Health Resources and Services Administration, 2011a).
In successful vaccine injury claims, the petitioner may receive compensation for pain and suffering, unreimbursed health care costs, unreimbursed wage loss, and future health care bills. In appropriate circumstances, death benefits may be awarded. In fiscal year 2010, petitioners' awards nationwide cumulatively exceeded $186,000,000 (U.S. Department of Health and Human Services, Health Resources and Services Administration, 2011b).
VACCINE INJURY TABLE
When the Vaccine Act was passed, the federal government created a table that listed all vaccines that were included in the VICP (Table) . The Table, known as the Vaccine Injury Table, also listed the injuries that were presumed to be caused by each vaccine. For example, the tetanus toxoid-containing vaccines administered to children were presumed to be the cause of an anaphylactic reaction if the anaphylactic reaction occurred within 4 hours following the vaccination (Table) . If a child received a tetanus toxoid-containing vaccine and subsequently developed brachial neuritis within 2 to 28 days following vaccination, then the Vaccine Court presumed the tetanus toxoid vaccination was the cause of the brachial neuritis.
If the petitioner substantiates that a vaccine injury, listed on the Vaccine Injury Table, occurred within the specific time frame listed on the Table for the onset of the injury, then the Vaccine Court turns to the respondent to hear a defense to the claim, if any. 
PROFESSIONAL PRACTICE
To defeat the petitioner's claim, the respondent must prove, by a preponderance of the evidence, that an alternative factor unrelated to the vaccination was the cause of the petitioner's injury. If the respondent fails to convince the Vaccine Court that it is more likely than not that some alternative factor unrelated to the vaccination caused the petitioner's vaccine injury, then the Court may decide to award compensation to the petitioner.
OFF-TABLE CLAIMS
Although the Vaccine Court began hearing claims of vaccine injuries listed on the Vaccine Injury 
SEASONAL INFLUENZA VACCINATION CLAIMS
All claims alleging a seasonal influenza vaccine injury are Off- Table  Claims. The Vaccine Injury Table does not list any injuries presumed caused by seasonal influenza vaccination. Therefore, the petitioner must file the claim and prove, by a preponderance of the evidence, that the vaccine was the substantial cause of the injury.
A recent Off- Table claim in Vaccine Court was brought by a petitioner who was 55 years old at the time he received the seasonal trivalent influenza vaccine on October 16, 2003. Approximately 3 weeks after vaccination, he was examined by a neurologist for complaints of tingling and numbness in his hands and legs. At that time, the neurologist reported that the petitioner's health history included antibiotics for bronchitis of about 1 month's duration.
At the beginning of the upper respiratory infection, the petitioner had tried azithromycin, cephalexin, and doxycycline without improvement. He was taking levofloxacin (500 mg) for bronchitis at tingling and numbness onset. The neurologist formed the impression that the petitioner had a mild acute sensory motor neuropathy that was seen in the context of a respiratory infection. Intravenous immunoglobulin was prescribed and the petitioner returned to work and playing tennis by May 2004.
More than 2 years later, in late September 2006, the petitioner saw his physician for complaints of 4 or 5 days of worsening of the residual symptoms that he had during the past 3 years after he was treated for Guillain-Barré syndrome. The petitioner stated that he had suffered from an upper respiratory infection about 2 weeks prior to this appointment. His physician formed the clinical impression that the petitioner's symptoms represented a return of the Guillain-Barré syndrome and "may represent a transition into an established chronic inflammatory demyelinating polyneuropathy condition" (Torday, 2009).
The petitioner filed a claim in Vaccine Court alleging that the seasonal influenza vaccination caused him to develop peripheral neuropathies such as Guillain-Barré syndrome. The respondent's defense to the petitioner's claim was that the Guillain-Barré syndrome was due to factors unrelated to the administration of the vaccine. The respondent argued that the petitioner's upper respiratory infection was the "factor unrelated" and the cause of Guillain-Barré syndrome. The Vaccine Court decided that the petitioner had shown, by a preponderance of the evidence, that the influenza vaccine caused him to develop Guillain-Barré syndrome. The Court was persuaded that the vaccine was a more likely cause of the Guillain-Barré syndrome than an unknown, unidentified viral pathogen argued by the respondent.
ELEMENTS OF A VACCINE INJURY CLAIM
Every successful seasonal trivalent influenza vaccine injury claim, including the above example, depends on the petitioner's ability to prove the following.
First, the petitioner must prove, by a preponderance of the evidence, that a medical theory causally connects the influenza vaccination and the petitioner's alleged injury. The first prong of proof routinely requires the petitioner to retain an expert physician witness willing and able to testify to the existence of a reliable medical theory, such as molecular mimicry, that causally connects the influenza vaccine to Guillain-Barré syndrome. In the above example, the respondent's expert witnesses agreed that molecular mimicry was a recognized medical theory. "The theory of molecular mimicry posits that autoimmune conditions may result when an invading pathogen contains a molecular sequence that resembles a sequence found in the body. The immune system, primed to attack the invader, inadvertently targets the body's own tissue, continuing the attack on the 'innocent' tissue even after destroying the invading pathogen" (Hennessey, 2010) .
Second, the petitioner must prove, by a preponderance of the evidence, that a logical sequence of cause and effect demonstrates that the influenza vaccination was the reason for the petitioner's alleged injury. The petitioner must show that the sequence of cause and effect is "logical and legally probable, not medically or scientifically certain" (Liable, 2000) . Treating physicians are likely to be in the best position to comment on whether a logical sequence of cause and effect exists to show that a vaccination was the reason for a particular individual's injury.
Third, the petitioner must prove, by a preponderance of the evidence, that a proximate temporal relationship exists between the influenza vaccination and the petitioner's al-PROFESSIONAL PRACTICE leged injury. In the above example, it was established by a preponderance of the evidence that the petitioner's neurologic symptoms started approximately 3 weeks after vaccination. The Court decided that 3 weeks was a medically appropriate time frame between influenza vaccination and onset of neurologic symptoms of Guillain-Barré syndrome (Torday, 2009) . The Court decided the case in the petitioner's favor and awarded monetary damages.
Each element of the vaccine injury claim must be proven by a preponderance of the evidence. A preponderance of the evidence standard requires the Court to believe that the existence of a fact is more likely than not likely.
THE CLINICIAN'S ROLE
Successful vaccine injury claims under the VICP depend, in large part, on clinicians' recognition of potential vaccine injuries and meticulous reporting of clients' health histories, including dates of vaccinations and dates of the onset of symptoms. Once health care practitioners recognize a potential vaccine injury, they can begin to scientifically investigate alternative causes for symptoms. The increased vigilance for vaccinerelated injuries will likely lead to improved adverse event reporting in the VAERS system and more useful information about vaccine safety.
